middle.news
How AFT Pharmaceuticals Plans to Triple Revenue by FY27 Amid Global Challenges
7:30am on Thursday 22nd of May, 2025 AEST
•
Pharmaceuticals
Read Story
How AFT Pharmaceuticals Plans to Triple Revenue by FY27 Amid Global Challenges
7:30am on Thursday 22nd of May, 2025 AEST
Key Points
Record FY25 revenue of NZD 208 million, up 6% from FY24
Operating profit of NZD 17.6 million, impacted by one-off events and growth investments
17% sales growth in Australia offsets challenges in Asia and international markets
Expanded R&D pipeline to 13 projects including novel treatments and licensing deals
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Aft Pharmaceuticals (ASX:AFP)
OPEN ARTICLE